Live Breaking News & Updates on Genetically Defined Liquid Tumors|Page 1

Stay updated with breaking news from Genetically defined liquid tumors. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Biomea Fusion Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights

Expanded clinical development footprint of BMF-219, the company’s lead investigational, orally administered, covalent menin inhibitor, to eight liquid and solid tumor indications and type 2. | March 28, 2023 ....

Thomas Butler , Biomea Fusion Inc , Exchange Commission , Development Rd Expenses , Securities Exchange , Company Nasdaq , Recent Clinical , Regulatory Highlights , Genetically Defined Liquid Tumors , Mutant Solid Tumors , Acute Leukemias , Investigational New Drug , System Discovery Platform , Cash Equivalents , Restricted Cash , Securities Act , Securities Exchange Act , Exchange Act , Biomea Fusion , Nc Stock Exchange , Press Release , Ype Bmea Us09077a1060 ,